Business
Bionik Laboratories to Present at the Joseph Gunnar & Co., LLC Pioneers 2016 Conference
Bionik Laboratories to Present at the Joseph Gunnar & Co., LLC Pioneers 2016 Conference.
About this update from Bionik Laboratories Corp.
[{"type":"text","content":"\n\n\n\nBionik Laboratories to Present at the Joseph Gunnar & Co., LLC Pioneers 2016 Conference\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nBionik Laboratories to Present at the Joseph Gunnar & Co., LLC Pioneers 2016 Conference\nCanada NewsWire\nTORONTO and BOSTON, May 2, 2016\n\n\n\n- Presentation with live webcast Thursday, May 5 at 3:30 p.m. ET -\n\n- Presentation to include Company's recent acquisition of Interactive Motion Technologies, Inc. - \n\n\n\nTORONTO and BOSTON, May 2, 2016 /CNW/ -- Bionik Laboratories Corp. (OTCQX: BNKL), a global pioneering robotics company focused on providing rehabilitation solutions to individuals with neurological disorders (\"Bionik\" or the \"Company\"), announced today that Peter Bloch, Chief Executive Officer and Chairman of the Board will present at the inaugural Pioneers 2016 presented by Joseph Gunnar & Co., LLC conference on Thursday, May 5, 2016 at 3:30 p.m. ET in New York, NY. \n\n\nMr. Bloch will provide a corporate update and will discuss Bionik's recent acquisition of Interactive Motion Technologies, Inc. (\"IMT\"), a Boston, Massachusetts-based global pioneer and leader in providing effective robotic tools for neurorehabilitation. \n\nThrough the acquisition of IMT, Bionik's product line now includes three upper extremity clinical rehabilitation products currently on the market for clinical use and two lower-body robots available for research use, being developed for clinical release. In addition the Company now has a potential pipeline to other new product candidates based on recent research being done at Massachusetts Institute of Technology (\"MIT\") by Hermano I. Krebs, Ph.D., M.S., Chief Science Officer of Bionik and Dr. Neville Hogan, who now serves as an advisor to the Bionik team. The clinical products have been characterized as Class II medical devices by the U.S. Food and Drug Administration (\"FDA\") and are currently sold in over 20 countries, including the United States. In addition, Bionik will maintain IMT's U.S. manufacturing facility based in Boston, Massachusetts, which is compliant with...